Basal Insulin and Bolus Insulin — Competitive Intelligence Brief

Basal Insulin and Bolus Insulin (Basal Insulin and Bolus Insulin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin therapy (basal-bolus regimen). Area: Diabetes.

phase 3 Insulin therapy (basal-bolus regimen) Insulin receptor Diabetes Small molecule

Target snapshot

Basal Insulin and Bolus Insulin (Basal Insulin and Bolus Insulin) — Rabin Medical Center. Basal-bolus insulin therapy mimics physiological insulin secretion by combining long-acting basal insulin for fasting glucose control with rapid-acting bolus insulin for postprandial glucose management.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Basal Insulin and Bolus Insulin TARGET	Basal Insulin and Bolus Insulin	Rabin Medical Center	phase 3	Insulin therapy (basal-bolus regimen)	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin therapy (basal-bolus regimen) class)

1. Rabin Medical Center · 1 drug in this class